1. Home
  2. KGEI vs ACOG Comparison

KGEI vs ACOG Comparison

Compare KGEI & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kolibri Global Energy Inc. Common stock

KGEI

Kolibri Global Energy Inc. Common stock

HOLD

Current Price

$4.11

Market Cap

163.1M

Sector

N/A

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$6.50

Market Cap

130.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KGEI
ACOG
Founded
2008
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
163.1M
130.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KGEI
ACOG
Price
$4.11
$6.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$11.00
$18.00
AVG Volume (30 Days)
71.3K
97.8K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
1.99
N/A
EPS
0.49
N/A
Revenue
$60,121,000.00
$7,427,199.00
Revenue This Year
$6.94
N/A
Revenue Next Year
$14.53
$143.70
P/E Ratio
$8.31
N/A
Revenue Growth
10.00
N/A
52 Week Low
$3.71
$3.75
52 Week High
$9.89
$11.54

Technical Indicators

Market Signals
Indicator
KGEI
ACOG
Relative Strength Index (RSI) 49.79 55.73
Support Level $3.94 $5.66
Resistance Level $4.11 $6.18
Average True Range (ATR) 0.15 0.41
MACD 0.06 0.09
Stochastic Oscillator 89.72 97.78

Price Performance

Historical Comparison
KGEI
ACOG

About KGEI Kolibri Global Energy Inc. Common stock

Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. The company derives a majority of its revenue from the United States.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: